The Food and Drug Administration's list of menopausal hormone therapy products with rewritten prescribing information now stands at nine, up from the six approved in February, after a page update dated October 30, 2026 added the estradiol patches Minivelle, Vivelle and Vivelle-Dot. On each of those labels, the boxed warning that for two decades named cardiovascular disease, breast cancer and probable dementia has been cut back to a single warning about endometrial cancer when estrogen is used without a progestogen in a woman who still has a uterus.

What changed on the label

The Vivelle-Dot prescribing information posted to the National Library of Medicine's DailyMed, revised October 2026 and effective October 30, shows the shape of the change. The boxed warning at the top of the label now covers only endometrial cancer with unopposed estrogen. The cardiovascular and breast cancer warnings have not disappeared; they remain in the Warnings and Precautions section further down the label, where the cardiovascular entry still lists active or prior deep vein thrombosis, pulmonary embolism and stroke as contraindications. The separate dementia subsection has been removed from Warnings and Precautions, with the Women's Health Initiative finding of an increased risk of probable dementia in women ages 65 to 79 now appearing under Geriatric Use. The Dosage and Administration section adds a new line asking prescribers to consider starting the drug in women under 60 or less than 10 years past menopause onset.

Those edits follow the template the FDA sent to every maker of menopausal hormone therapy on November 10, 2025. According to the agency's own description of that request, the boxed warning language on cardiovascular disease, breast cancer and probable dementia was to come out of all products, systemic and vaginal; the endometrial cancer box was to stay only on systemic estrogen-alone products; the long-standing instruction to use the lowest dose for the shortest time was to be dropped; and labels for local vaginal estrogen were to be condensed.

Which products, and when

The FDA approved the first six revised labels on February 12, 2026, spanning four categories: progestogen alone (Prometrium), systemic estrogen alone (Divigel, Cenestin, Enjuvia), topical vaginal estrogen (Estring) and combined systemic estrogen and progestogen (Bijuva). The agency said at the time that 29 companies had submitted proposed labeling changes at its request. The October 30 update to the FDA's list added the three estradiol transdermal systems. The Department of Health and Human Services issued a press release the same day; that release could not be opened for this article, so its contents are not reported here.

What the agency said the evidence showed

The FDA's position, laid out in its November 2025 announcement and repeated in February, rests on its reading of the Women's Health Initiative. The agency notes that the average participant in that trial was about 63 years old, well past the age at which hot flashes typically begin, and that the formulation studied is no longer in common use. It describes the breast cancer signal in the trial as a statistically non-significant increase in diagnoses. Against that, the agency cites randomized studies in which women who began therapy within 10 years of menopause onset, generally before age 60, had lower all-cause mortality and fewer fractures. The FDA also framed the change as a response to underuse: by its count, roughly 2 million women ages 46 to 65 received a hormone therapy prescription in 2020, out of about 41 million women in the age range.

What has not changed

The approved uses are the same: moderate to severe hot flashes and night sweats, vaginal dryness and discomfort, and prevention of bone loss after menopause. Systemic estrogen-alone products keep a boxed warning. The cardiovascular and breast cancer warnings stay on systemic product labels, lower on the page. The contraindications are unchanged. And the FDA's own request document is explicit that the revisions do not declare hormone therapy free of cardiovascular, cancer or cognitive risk; they change how those risks are presented and add the age and timing context.

Where The Menopause Society stands

The Menopause Society, the professional body formerly known as the North American Menopause Society, responded to the FDA on November 10, 2025. In that statement it agreed with removing the boxed warning from low-dose vaginal estrogen, which it considers a safe and effective treatment for genitourinary symptoms that the warning may have discouraged. On systemic estrogen, the society's statement is more guarded: it says those products still carry potential risks for certain women, that risk is lower for younger, healthy women who start close to the menopause transition and higher for women who start later or further from menopause onset, and that comorbidities, personal and family history, symptoms and preferences all belong in the conversation before starting. The society's statement points readers to its hormone therapy position statement. As of this writing, the most recent one listed on its website is the 2022 statement; no 2026 position statement appears there.

The updated labels for all nine products are linked from the FDA's prescribing information page. For a woman weighing or already using one of these products, the questions the new label itself raises, age at start, time since menopause, uterus status and personal cardiovascular and breast cancer history, are the ones to bring to a clinician.

This article reports research and expert guidance. It is not medical advice. Talk to your clinician before changing medication, treatment or a medical diet.

Sources